Diego Rielo, MD
Neurology · Hialeah, FLNPI 1720058233
Payments from drug & device makers
Across 41 payments — averaging $17,239 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$344K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$167K
- Acadia Pharmaceuticals Inc$121K
- Sage Therapeutics, LLC$46K
- Novartis$21K
- AbbVie$6K
- plus $1K from 9 others
Across 2 payments — averaging $848.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
What the payments were for
- Food & beverage$3025%
- Gifts$6,01095%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 1 | $344,328 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $167,063 |
| Acadia Pharmaceuticals Inc | 15 | $120,902 |
| Sage Therapeutics, LLC | 5 | $46,059 |
| Novartis | 1 | $21,048 |
| AbbVie | 2 | $6,016 |
| Eli Lilly | 1 | $653 |
| E.r. Squibb & Sons, L.L.C. | 1 | $485 |
| Avanir Pharmaceuticals, Inc. | 4 | $71 |
| Livanova USA, Inc. | 1 | $47 |
| Adamas Pharmaceuticals, Inc. | 2 | $43 |
| UCB, Inc. | 1 | $30 |
| Amgen | 1 | $28 |
| Genentech USA, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$6,010
How this compares
$706,808 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 13 | $5,484 |
| Memantine Hcl | 31 | $2,909 |
| Levetiracetam | 61 | $2,862 |
| Entacapone | 17 | $2,527 |
| Lacosamide | 15 | $2,066 |
| Oxcarbazepine | 14 | $1,654 |
| Scopolamine | 11 | $1,619 |
| AmantadineAmantadine Hcl | 16 | $1,324 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 14 | $1,237 |
| Pregabalin | 22 | $1,121 |
| Buspirone Hcl | 15 | $1,065 |
| Divalproex Sodium | 31 | $1,050 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $1,006 |
| Lamotrigine | 60 | $978 |
| Gabapentin | 29 | $782 |
Paid to pharmacies, not to this prescriber.
Other neurology in Hialeah
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.